SPTX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Seaport Therapeutics, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 21.10 USD
1.2% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is - below the Trend Line and sits at 76.7% of its 52-week range. The latest completed week returned 1.2%, after a -1.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 45d.

Setup score 38 out of 100
Latest Close 21.10 USD 24 Jul 2026
1W Return 1.2% latest completed week
4W Return -1.4% short-term follow-through
12W Return 6.4% quarterly tape
Trend Breadth 0.0% 0 of 13 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Next-week expectancy is positive at 61.79% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • 2 reversal markers appear in the recent smart-money tape.
What to watch next
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.2% Latest completed week; four-week move -1.4%. Indicator stack 0/50 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 61.79% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 51/100 34 relevant articles in the latest sentiment read. Event risk 45d Next report is scheduled for 14 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is - below the Trend Line and sits at 76.7% of its 52-week range. The latest completed week returned 1.2%, after a -1.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0912-week average 0.03

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.09Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -1.4% over four weeks, 6.4% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W1.2%
4W-1.4%
12W6.4%
26W-
52W-
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 42% Model confidence 41%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength78/100Blend of value, momentum, and quality. Underlying universe rank 23; rank 1 is best.
Value64/100Relative valuation strength. Underlying universe rank 37; rank 1 is best.
Quality62/100Profitability and accounting quality. Underlying universe rank 39; rank 1 is best.
Momentum64/100Medium-term price momentum. Underlying universe rank 37; rank 1 is best.
Growth64/100Revenue and earnings growth. Underlying universe rank 37; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-7.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.6x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 34 relevant articles.

4 positive · 27 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings45dNext report is scheduled for 14 Sep 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-8.3%Distance below the 52-week high.
13-week volatility8.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher8 of 124 weeks finished lower.
Best week+17.8%Week of 26 Jun.
Worst week-19.1%Week of 8 May.
Latest week+1.2%Week of 24 Jul.

Shape of recent returns

Strong gains5
Modest gains3
Flat weeks0
Modest losses2
Sharp losses2
Recent vol8.9%13-week weekly-return volatility.
Base vol8.9%52-week weekly-return volatility.
Up/down split8/4Count of positive and negative weeks in the 52-week window.
Average skew5.9% / -9.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape35/100

Trend, activity pressure, participation, and risk combine to a 35/100 tape read.

 Indicator analysis6/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.09; 2 reversal markers Next-Week ExpectancyPositive 61.79%

Next-week expectancy is positive with a 61.79% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors67/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 45; Small Cap Core rank 45 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 34 relevant articles.

Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings45d

Next report is scheduled for 14 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202621.10 USD1.2%-18.96 USD0.00-442.4KOff
17 Jul 202620.85 USD-3.4%-18.78 USD0.00-568.1KOff
10 Jul 202621.58 USD4.9%-18.59 USD0.00-759.4KOff
3 Jul 202620.57 USD-3.9%-18.30 USD0.00-962.8KOff
26 Jun 202621.40 USD17.8%-18.04 USD0.00-1.4MOff
19 Jun 202618.17 USD0.9%-17.62 USD0.00-1.9MOff
12 Jun 202618.00 USD9.5%-17.55 USD0.00-643.0KOff
5 Jun 202616.44 USD-9.6%-17.47 USD0.00-595.6KOff
29 May 202618.19 USD3.9%-17.68 USD0.00-729.0KOff
22 May 202617.50 USD4.1%-17.55 USD0.00-1.3MOff
15 May 202616.80 USD4.7%-17.57 USD--2.0MOff
8 May 202616.05 USD-19.1%-17.95 USD--3.0MOff
1 May 202619.84 USD--19.84 USD--4.7MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.